Yumi Sato

Yumi Sato is Executive Vice President, Chief Corporate Strategy Officer of Sunovion Pharmaceuticals Inc., a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. She is a member of the Sunovion Executive Leadership Team, as well as an Executive Officer of Sunovion’s parent company, Sumitomo Dainippon Pharma Co., Ltd.

Ms. Sato is responsible for helping guide business strategy for Sunovion and advancing the Company’s track record of discovery, development and commercialization of important therapies. She joined Sunovion in 2020 and oversees Corporate Strategy, New Product Planning, Business Development, Alliance Management and other functions contributing to the organization’s sustainability.

Ms. Sato has more than 25 years of experience in drug development. Most recently she served as Senior Director, Global Corporate Strategy for Sumitomo Dainippon Pharma, leading the Company’s development of the Mid-Term Business Plan 2022. Previously, Ms. Sato led Regulatory Affairs and Clinical Research functions, which entailed extensive collaboration with the Sunovion Global Clinical Development organization. She began her career in the research division of Sumitomo Pharmaceuticals.

Ms. Sato earned a Master’s degree in pharmaceutical sciences at the University of Tokyo.